AstraZeneca invests USD 2 billion in Summit Therapeutics for 12% stake
Bitget2026/09/29 06:08- AstraZeneca agreed to invest USD 2 billion in newly issued equity in Summit Therapeutics to accelerate development of ivonescimab.
- Investment buys about 109,000 preferred shares convertible to common stock at a 1:1,000 ratio.
- Stake equates to about 12% of Summit’s outstanding common stock, or about 10.6% on a fully diluted basis.
- Closing is expected within one week; any future conversion to common stock requires customary regulatory clearances.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Production Increase Falls Short, Layoffs First! Boeing (BA.US) Cuts 5% of Commercial Airplane Jobs, Delays 737 Monthly Production Target of 47 Aircraft to 2027
Stephanie Pope, head of Boeing's commercial airplanes division, informed employees in an internal memo on Monday that due to obstacles in increasing aircraft production, the division plans to cut 5% of its workforce.
After acquiring SpotHero, Uber (UBER.US) makes its debut in the parking sector with a parking space reservation feature, initially available in 15 U.S. cities
Uber has launched a brand new parking space reservation feature, which marks its first step in the parking sector following its acquisition of the parking app SpotHero earlier this year.
Crypto prices
More
